Expert Video - How common is treatment failure and relapse in AML?
Dr. Jamile Shammo, an expert on acute myeloid leukemia (AML), describes how common treatment failure and relapse is in AML. Unfortunately, relapse is common in AML. About half of people who go into remission will have a relapse of their leukemia. Treatment failure in the form of primary resistance to chemotherapy is less common in people under 60. She explains that in people under 60, about 35 percent experience treatment failure. In people over 60, treatment failure may be close to 50 percent. She also explains that the majority of relapses occur within two to three years of initial treatment.
Share with family and friends:
Click here to take our SURVEY Your feedback is important to us! We will use your feedback to develop future areas of content about AML which will help other patients, caregivers and families.
This educational activity has been developed by the Myelodysplastic Syndromes Foundation, Inc. and Mechanisms in Medicine Inc.
This activity is supported by educational grants from AbbVie, Acceleron, Bristol-Myers Squibb, Celgene Corporation, Daiichi Sankyo, Jazz Pharmaceuticals and Takeda Oncology.
This website is part of the Animated Patient™ series developed by Mechanisms in Medicine Inc., to provide highly visual formats of learning for patients to improve their understanding, make informed decisions, and partner with their healthcare professionals for optimal outcomes.